Mary Ann Lumiqued

Program Management Global Head responsible for advancing the development plans of Tubulis’ emerging antibody drug conjugate (ADC) pipeline by working with the various functions (Preclinical, Biomarker, CMC, Quality, Clinical) to effectively strategize, plan, and execute on the multiple oncology programs from development candidate selection, clinical development, regulatory submission and approvals, and commercial launch.

Responsible for developing and executing the process for the Medical Affairs strategy and tactical plans. Lead MA operations in close partnership with the leadership team, and drive alignment among external and internal partners in R&D and Commercial. Develop and execute the process for the medical strategy for MONJUVI/ tafasitamab, felzartamab, and future products.

Program Leader for MONJUVI / tafasitamab, the first FDA approved product within organization. Also with multiple trials ongoing and planned in Phase 1, 2 and 3 to treat B-cell malignancies including Diffuse Large B-Cell lymphoma, Follicular Lymphoma and Chronic Lymphocytic Leukemia. Lead cross-functional Global Program Team and Working Groups to develop, implement and achieve the overall program strategy and project objectives.

• Led Core Teams of two commercial products to advance the overall strategy of the brands. Liaised among Upper Management, Teams and business partners to ensure corporate and team goals are achieved. • Directed operational teams supporting the various lifecycle management and development programs to ensure activities aligned with the internal strategy. • Drove cross-functional teams to produce the Strategic Plans, Integrated Development Plans, Target Product Profiles and Executive Summaries.

• Established cross-functional commercial teams for the therapeutic area groups with focus on thorough planning and more appropriate coordination and communication within and across products and functions, and between the U.S. Affiliate and headquarters. • With teams, developed and executed the strategic and annual tactical plans comprised of budgets, forecasts, timelines and key performance indicators (KPIs). • Managed Canadian partnership with EMD Serono.

• Initiated, implemented and maintained the project management discipline within organization. Presented strategy and updates to Senior Management and Board. Managed program reviews with strategic drug development partner. • Led cross-functional Teams for drug candidates in Phases 1-3. Identified critical path activities and implemented mitigation strategies. • Developed Target Product Profiles utilized for strategic portfolio analyses.

• Led, managed and facilitated multiple cross-functional meetings (Core, CMC, Clinical-Regulatory, Launch, Device and Pre-Approval Inspection) for drug and drug-device programs in all phases of development. Core Team co-lead for company’s first approved product. • Designed and improved project management systems throughout the organization: risk mitigation and contingency planning, project opportunity assessments, lessons learned, go/no-go decision points. • Managed alliance with Bristol-Myers Squibb.

• Supported lead scientists, postdoctoral fellows and graduate students with experiments and programs related to dental research.

• Conducted research (how stress and alcohol affect the brain) and gathered data required for final analysis. • Taught and managed part time students performing experiments.

Detail-oriented Biopharmaceutical Project Management Professional (PMP) with over 20 years of experience leading drug and drug/device combination programs in all phases of development (Preclinical, Clinical, BLA/NDA/PMA/510(k) Filing, Approval) and commercialization (launch, lifecycle management). Experience in Oncology (solid tumors and haematology-oncology), Neurology, Endocrinology, Ophthalmology, Pain Management, Inflammation and Cardiovascular disease

Biology, Psychology